Allogeneic cell therapies “poised for prime time” says expert
As cell and gene therapy developers struggle against an investment slump and competition from established autologous treatments, allogeneic cell therapies…
All articles by Frankie Fattorini
Frankie Fattorini
Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.
-
-
Amid deglobalising trade, experts seek AI safeguards for clinical trial supply
The role of AI in supply chain management proved to be the focal issue at the recent 2025 Clinical Trial…
-
Are European biopharma manufacturers ‘nearshoring’?
In step with international news in recent times, European pharma and biotech are leaning towards ‘nearshoring’, preferring domestic operations to…
-
Machine learning adoption into supply chain management on the horizon
Widespread integration of machine learning (ML) into supply chain management by major pharma suppliers is just a few years away,…
-
New EU trial regulations could expedite approvals and address shortages
A major overhaul and consolidation of EU clinical trial regulations is paving the way to faster approvals, greater international coordination,…
-
Mandatory drug stock monitoring empowers EU to tackle shortages
Earlier this month, the newly empowered role of the European Union (EU)’s Executive Steering Group on Shortages and Safety of…
-
Supply chain uncertainties present opportunities for biopharma couriers in 2025
Despite concerns of supply chain fragility as geopolitical tensions mount, global biopharma courier Biocair is braced for a surge in…
-
Supply chains and AI take precedence at European clinical trial meeting
As global supply chains come under increasing strain and AI disrupts how clinical trials are conducted, experts will congregate to…
-
Radiopharmaceutical deals drive sector growth despite supply crisis
A reinvigorated interest in radiopharmaceuticals has brought nuclear medicine to the foreground with deals over 2024 further exemplifying this trend.…
-
NVIDIA champions Innophore partnership to model drug dynamics with AI
NVIDIA and Innophore’s collaborative artificial intelligence (AI)-driven, drug safety screening platform CavitOmiX is set to launch in late January 2025,…